|
Volumn 8, Issue 7, 2005, Pages 573-577
|
Use of high-content analysis for compound screening and target selection
a
UCB PHARMA
(Belgium)
|
Author keywords
Cell based screening; Drug discovery; High content analysis; Target validation
|
Indexed keywords
ADALIMUMAB;
BCR ABL PROTEIN;
ETANERCEPT;
G PROTEIN COUPLED RECEPTOR;
IMATINIB;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
INFLIXIMAB;
NEW DRUG;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;
PHOSPHOTRANSFERASE INHIBITOR;
PLATELET DERIVED GROWTH FACTOR;
PROTEIN INHIBITOR;
PROTEIN KINASE B;
RNA;
ROSIGLITAZONE;
STEM CELL FACTOR RECEPTOR;
TRANSCRIPTION FACTOR;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
ANALYTIC METHOD;
ARTICLE;
CELL ASSAY;
CELL DIFFERENTIATION;
CELL TRANSFORMATION;
COMPETITIVE INHIBITION;
CYTOTOXICITY;
DRUG DESIGN;
DRUG IDENTIFICATION;
DRUG INDUSTRY;
DRUG RECEPTOR BINDING;
DRUG RESEARCH;
DRUG SCREENING;
DRUG TARGETING;
GENETICS;
HUMAN;
NERVE CELL GROWTH;
PROCESS OPTIMIZATION;
PROCESS TECHNOLOGY;
PROTEIN BINDING;
PROTEIN FUNCTION;
PROTEIN PHOSPHORYLATION;
PROTEIN TARGETING;
RHEUMATOID ARTHRITIS;
RNA INTERFERENCE;
SIGNAL TRANSDUCTION;
STRUCTURE ACTIVITY RELATION;
ANIMALS;
CHEMISTRY, PHARMACEUTICAL;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
TECHNOLOGY, PHARMACEUTICAL;
|
EID: 21344452806
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (12)
|
References (10)
|